Aegerion Pharmaceuticals said today that the FDA had approved lomitapide (Juxtapid) to help further lower cholesterol in patients with homozygous familial hypercholesterolemia. The approval comes with ...

Please provide your email address to receive an email when new articles are posted on . Lomitapide was approved for treatment of homozygous familial hypercholesterolemia in children as young as 2 ...

Are you taking Lomitapide? Are you aware of the dangers of combining Lomitapide with certain foods, herbs, or alcohol? Drug-food-interactions are seldom discussed but can lead to undesirable side ...

In briefing documents ahead of an advisory committee meeting on October 17, an FDA panel stated, "In considering a risk management program for lomitapide, FDA must keep in mind that the HoFH patient ...

Homozygous familial hypercholesterolemia is a rare genetic condition that is often characterized by an increased risk of premature cardiovascular (CV) events and cardiac death. Lomitapide decreases ...

Review the side-effects of Lomitapide as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In majority of the ...

A total of 46 pediatric patients were enrolled, with 43 patients completing the run-in phase and entering the efficacy phase. 20 patients were between 5 and 10 years of age. 23 patients were between ...

Please provide your email address to receive an email when new articles are posted on . Patients with adult homozygous familial hypercholesterolemia responded favorably to lomitapide when administered ...

FDA reviewers have raised no new concerns about lomitapide ahead of a Wednesday meeting of the Endocrinologic and Metabolic Drugs Advisory Committee. The FDA today released briefing documents that ...

London, UK - The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended that the lomitapide preparation Lojuxta (Aegerion Pharmaceuticals) be ...

Lomitapide (trade name: Lojuxta) has been available since July 2013 as additional treatment for adults with homozygous familial hypercholesterolaemia in whom diet and other drugs do not sufficiently ...

Cambridge, MA - Aegerion Pharmaceuticals says it is preparing regulatory filings in the US and Europe for its "orphan" drug lomitapide, a small-molecule microsomal triglyceride transfer protein ...